Therapeutic efficacy of Chymotrypsin in acute bovine mastitis

Therapeutic efficacy of Chymotrypsin in acute bovine mastitis

Objetivo. Evaluar la eficacia terapéutica del fármaco proteolítico “quimotripsina”, en tratamientos conjuntos con un antibiótico betalactámico en vacas con mastitis aguda. Material y métodos. Se evaluaron el conteo de células somáticas (CCS) y los hallazgos semiológicos, comparando la eficacia con un grupo de animales en donde sólo fue utilizado el antibiótico. Resultados. Los resultados revelaron eficacia clínica (disminución del CCS, p<0.01) y ausencia de signos clínicos agudos en el 84.7% de los cuartos observados, incluso observándose respuesta anti-inflamatoria desde las primeras horas del tratamiento. El restante 15.3% también presentó eficacia clínica a la terapia aunque la respuesta fue moderada en comparación con el 84.7% de los casos que tuvieron la respuesta acelerada. Conclusiones. Lo anterior permite concluir que el uso de quimotripsina en casos de mastitis aguda, acelera la respuesta en la glándula mamaria infectada e inflamada, con mayor eficacia que los tratamientos con sólo amoxicilina + ácido clavulánico.

Objective. To evaluate the therapeutic efficacy of a proteolytic drug “chymotrypsin” combined with beta-lactam antibiotics in cows with acute mastitis. Material and Methods. Fourteen cows with acute mastitis. Three cows were treated with a beta-latam antibiotic (BLA) and the other eleven cows were treated with chymotrypsin plus beta-lactam antibiotic (C+BLA). The response was evaluated according to the semiological findings, somatic cell count (SCC) and a microbiological culture. Results. There was a therapeutic efficacy comparing the pre and post treatment period (SCC reduction, p<0.01) and a reduction of clinical signs in 84.7% of treated quarters in the first day of treatment (C+BLA) compared with (BLA). Conclusions. Chymotrypsin improves the treatment of acute mastitis when is combined with BLA, controlling the infected mammary glands, compared with the group treated only with amoxicilina and clavulanic acid.

1. Petrovski KR, Trajcev M, Buneski G.A. Review of the factors affectingthe costs of bovine mastitis. J S Afr Vet Assoc 2006; 77(2):52-60. http://dx.doi.org/10.4102/jsava.v77i2.344
3. Ericsson UH, Lindberg A, Persson WK, Ekman T, Artursson K, Nilsson OM et al. Microbial etiology of acute clinical mastitis and agent-specific risk factors. Vet Microbiology 2009; 137(1-2):90-7.
4. http://dx.doi.org/10.1016/j.vetmic.2008.12.005
6. Hogeveen H, Kamphuis C, Steeneveld W, Mollenhorst H. Sensors and clinical mastitis--the quest for the perfect alert. Sensors (Basel, Switzerland) 2010; 10(9):7991-8009. http://dx.doi.org/10.3390/s100907991
8. Kim Y, Atalla H, Mallard B, Robert C, Karrow N. Changes in Holstein cow milk and serum proteins during intramammary infection with three different strains of Staphylococcus aureus. BMC Vet Res 2011; 7(1):51. http://dx.doi.org/10.1186/1746-6148-7-51
10. Nagahata H, Kawai H, Higuchi H, Kawai K, Yayou K, Chang CJ. Altered leukocyte responsiveness in dairy cows with naturally occurring chronic Staphylococcus aureus mastitis. J Vet Med Sci 2011; 73(7):885-94. http://dx.doi.org/10.1292/jvms.10-0379
12. Zhao X, Lacasse P. Mammary tissue damage during bovine mastitis: causes and control. J Anim Sci 2008; 86(13):57-65. http://dx.doi.org/10.2527/jas.2007-0302
14. Barkema HW, Schukken YH, Zadoks RN. Invited Review: The role of cow, pathogen, and treatment regimen in the therapeutic success of bovine Staphylococcus aureus mastitis. J Dairy Sci 2006; 89(6): 1877-95. http://dx.doi.org/10.3168/jds.S0022-0302(06)72256-1
16. McDougall S, Bryan M, Tiddy RM. Effect of treatment with the nonsteroidal antiinflammatory meloxicam on milk production, somatic cell count, probability of re-treatment, and culling of dairy cows with mild clinical mastitis. J Dairy Sci 2009; 92(9):4421-31. http://dx.doi.org/10.3168/jds.2009-2284
18. Rantala M, Kaartinen L, Välim&aki E, Stryrman M, Hiekkaranta M, et al. Efficacy and pharmacokinetics of enrofloxacin and flunixin meglumine for treatment of cows with experimentally induced Escherichia coli mastitis. J vet Pharmacol Therap 2002; 25(4):251-8 http://dx.doi.org/10.1046/j.1365-2885.2002.00411.x
20. Banting A, Banting S, Heinonen K, Mustonen K. Efficacy of oral and arenteral ketoprofen in lactating cows with endotoxin-induced acute mastitis. Vet Rec 2008; 163:506-509 http://dx.doi.org/10.1136/vr.163.17.506
22. Fajt V, Wagner S, Norby B. Analgesic drug administration and attitudes about analgesia in cattle among bovine practitioners in the United States. J Am Vet Med Assoc 2011; 238(6):755-767. http://dx.doi.org/10.2460/javma.238.6.755
24. Ziv G, Shem-Tov M, Ascher F. Combined effect of ampicillin, colistin and dexamethasone administered intramuscularly to dairy cows on the clinico-pathological course of E. coli-endotoxin mastitis. Vet Res 1998; 29(1):89-98.
26. Kania B, Kania K. Pharmacological and toxicological aspects of combination of beta-lactam and aminoglycoside antibiotic, prednisolone and procaine hydrochloride on the example of Vetramycin. Pol J Vet Sci 2003; 6(4):279-296.
28. Kruger M. Untersuchungen zum einfluss der proteolytischen enzyme trypsin, chymotrypsin und papain auf euterpathogene mikroorganismen. Tierarztl Prax 1999; 27:207-215.
30. Drillich M, Raab D, Wittke M, Heuwieser W. Treatment of chronic endometritis in dairy cows with an intrauterine application of enzymes. A field trial. Theriogenology 2005; 63(7):1811-23. http://dx.doi.org/10.1016/j.theriogenology.2004.05.031
32. Kwiecinski J, Josefsson E, Jin T. Fibrinolysis is down-regulated in mouse collagen-induced arthritis, but its normalization does not alleviate the course of disease. Inflamm Res 2011; 60(11):1021-9. http://dx.doi.org/10.1007/s00011-011-0363-0
34. Szaba F, Smiley S. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002; 99:1053-1059. http://dx.doi.org/10.1182/blood.V99.3.1053
36. Chuaqui, B., González, S. Manual de Patología General. segunda edicián. Universidad Catálica de Chile: Santiago de Chile; 1999
38. Levi M, Keller T, Gorp VE, Cate TH. Infection and inflammation and the coagulation system. Cardiovascular research 2003; 60:26-39. http://dx.doi.org/10.1016/S0008-6363(02)00857-X
40. Levi M, van der Poll T. Inflammation and coagulation. Critical care medicine 2010; 38(2):S26-34. http://dx.doi.org/10.1097/CCM.0b013e3181c98d21
42. Biemond B, Levi M, Cate TH. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: Effect of interventions in the cytokine and coagulation cascades. Clin Sci 1995; 88:587-594. http://dx.doi.org/10.1042/cs0880587
44. Van der Poll T, Levi M, Buller H. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174:729-732. http://dx.doi.org/10.1084/jem.174.3.729
46. Sazonova IY, Thomas BM, Gladysheva IP, Houng K, Reed GL. Fibrinolysis is amplified by converting alpha-antiplasmin from a plasmin inhibitor to a substrate. J Thromb Haemost. 2007; 5(10):2087-94. http://dx.doi.org/10.1111/j.1538-7836.2007.02652.x
48. Kwiecinski J, Josefsson E, Mitchell J, Higgins J, Magnusson M, Foster T, et al. Activation of plasminogen by staphylokinase reduces the severity of Staphylococcus aureus systemic infection. J Infect Dis. 2010; 202(7):1041-9. http://dx.doi.org/10.1086/656140
50. Jin T, Bokarewa M, McIntyre L. Fatal outcome of bacteraemic patients caused by infection with staphylokinase-deficient Staphylococcus aureus strains. J Med Microbiol 2003; 52:919-39.
51. http://dx.doi.org/10.1099/jmm.0.05145-0
53. Guo Y, Li J, Hagström E, Ny T. Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice. PloS one 2011; 6(9):e24774. http://dx.doi.org/10.1371/journal.pone.0024774
55. Kivaria FM, Noordhuizen JP, Nielen M. (2007). Interpretation of California mastitis test scores using Staphylococcus aureus culture results for screening of subclinical mastitis in low yielding smallholder dairy cows in the Dar es Salaam region of Tanzania. Prev Vet Med, 2007; 78(3-4):274-85. http://dx.doi.org/10.1016/j.prevetmed.2006.10.011
57. Oliver, S. Antimicrobial resistance of Mastitis pathogens. Vet Clin Food Anim 28 (2012) 165−185. http://dx.doi.org/10.1016/j.cvfa.2012.03.005
59. García, B. Pedro. Inflamacián. Rev.R.Acad.Cienc.Exact.Fís.Nat. (Esp) Vol. 102, N°. 1, pp 91-159, 2008 IX Programa de Promocián de la Cultura Científica y Tecnolágica.